Radiographic progression-free survival as a surrogate endpoint for overall survival in first-line ARPi naïve metastatic castration-resistant prostate cancer

Results suggest rPFS is a valid surrogate for OS in first-line ARPi naïve mCRPC per IQWiG criteria. A statistically significant OS effect can be inferred for a trial demonstrating an upper confidence limit of HR < 0.83 in rPFS.